Up­dat­ed: J&J ax­es four-year dis­cov­ery al­liance with Mor­phic

J&J and Har­vard spin­out Mor­phic Ther­a­peu­tic are part­ing ways af­ter four years of work­ing to­geth­er on find­ing small mol­e­cule drugs that can act on new in­te­grin tar­gets.

Mor­phic qui­et­ly dis­closed on Fri­day that it re­ceived a ter­mi­na­tion no­tice from J&J’s Janssen a week ago. Ab­b­Vie broke off a sim­i­lar deal with Mor­phic back in June. In its fil­ing, the biotech did not spec­i­fy why Janssen walked away, not­ing on­ly that the phar­ma part­ner ex­er­cised its right to end the R&D col­lab­o­ra­tion “for con­ve­nience.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.